A Prospective, Observational Study to Assess the Long-Term Safety of Abrocitinib Treatment in Adult Patients with Moderate-to-Severe Atopic Dermatitis First published 13/01/2025 Last updated 13/01/2025 EU PAS number:EUPAS1000000420 Study Planned